Printer Friendly

Non-alcoholic fatty liver disease in subjects with non-functioning adrenal adenomas/Fonksiyon gostermeyen adrenal adenomlu kisilerde non-alkolik yagli karaciger hastaligi.


Subsequent to the recognition of increased prevalence of obesity, glucose intolerance and hypertension in subjects with adrenal adenomas, a variety of metabolic and cardiovascular disturbances have been identified in those individuals (1-4). Previously, we showed several aspects of unfavorable metabolic and cardiovascular outcome in terms of elevated uric acid, the homeostasis model assessment (HOMA) and D-dimer levels and increased carotid intima media thickness in individuals with silent adrenal adenomas mainly in older ages (5,6).

Non-alcoholic fatty liver disease is a clinical situation between simple steatosis and steatohepatitis. Several aetiological factors have been described including Type 2 diabetes mellitus (Type 2 DM), obesity and metabolic syndrome as the leading causes (7). Recent studies have provided several lines of evidence that could be attributable to the hypothalamus-pituitary-adrenal (HPA) axis alterations in fatty liver disease and non-alcoholic steatohepatitis (NASH) (8-11).

Current literature has suggested that clinically non-functioning adrenal adenomas may not be completely "silent" in terms of cortisol secretion. In vivo data demonstrated that steroid production in inactive adrenocortical tumors was not overtly different from those of subclinical Cushing's syndrome (12). We also showed that, subjects with non-functioning adrenal adenomas featured subtle cortisol autonomy in terms of elevated post dexamethasone cortisol and reduced dehydroepiandrostenedione sulfate levels when compared to healthy subjects (5,6).

In this study, we aimed to investigate NAFLD prevalence in 130 consecutive individuals with non-functioning adrenal adenomas. For this purpose, we included 20 subjects with Cushing's syndrome and 170 age-, gender-and BMI-matched individuals without adrenal gland disorders as control subjects.

Materials and Methods

This retrospective study was conducted in Dokuz Eylul University, Division of Endocrinology. Data of 200 consecutive subjects, who were referred to our institute due to incidentally discovered adrenal tumors between January 2007 and January 2009, were evaluated. Among those, 130 individuals, who had non-functioning adrenal adenomas, were included in the study. Control group was generated from the patients of our obesity and diabetes units of the division. Data of control subjects were achieved consecutively from their medical records. Age, gender and BMI were matched between non-functioning adrenal adenoma and control groups. The essential criterion for the inclusion of control subjects was the presence of an abdominal ultrasonography providing adequate data regarding liver parenchyma and adrenal glands. We also included 20 consecutive subjects with Cushing's syndrome (Cushing Disease n=10, ACTH independent Cushing's syndrome due to an adrenal adenoma n=10) in order to investigate the prevalence of hepatosteatosis in hypercortisolemic individuals.

Exclusion criteria for all participants were: chronic liver disease, chronic kidney disease, malignancy, and lack of ultrasonography examination or inappropriate ultrasonography findings.

Liver steatosis was assessed on a three-point scale (mild, moderate or severe), based on ultrasonographic characteristics. Mild steatosis was defined as a slight augmentation in liver echogenicity and a weak exaggeration of echogenic discrepancy between liver and kidney. Moderate steatosis was defined as a loss of echo line in the portal vein wall, particularly from the peripheral branches, resulting in a featureless appearance of the liver. Severe steatosis was defined as much greater reduction in echo penetration and a large echo discrepancy between liver and kidney (13-15)

Non-alcoholic fatty liver disease was diagnosed in subjects with fatty liver who met the following criteria: alcohol consumption <20 g/day, no history of chronic viral hepatitis, autoimmune hepatitis or liver cirrhosis, and no use of toxins or drugs associated with steatosis [16]. Alcohol consumption was assessed by detailed history. Viral hepatitis and autoimmune hepatitis markers were measured in subjects who had elevations in either ALT or GGT, without a definite underlying etiology, more than 3 months. Four subjects in control group were further evaluated by liver biopsy due to the persistently elevated ALT levels and were diagnosed with non-alcoholic steatohepatitis. Initial radiological examination was computed tomography (CT) in all subjects with incidentally discovered adrenal tumors. Malignancy was excluded if the following criteria were met in CT evaluations: (i) regular shape with well-defined margins and homogenous (ii) attenuation value of 10 or less Hounsfield units on unenhanced CT scan, and (iii) 30 or less Hounsfield units on enhanced CT scan. Radiological examination depended on the etiology of hypercortisolism in subjects with Cushing's syndrome. The definitive diagnosis was Cushing Disease in 10 subjects and ACTH-independent Cushing's syndrome due to an adrenal adenoma in 10 subjects. Adrenal imaging was not performed in subjects with Cushing Disease. In control subjects, adrenal glands were evaluated by ultrasonography

Hormonal evaluation was performed in all subjects with incidentally discovered adrenal tumors and Cushing's syndrome. Morning cortisol, dehydroepiandrosterone sulfate (DHEA-S), adrenocorticotrophic hormone (ACTH), and, in hypertensive subjects, plasma renin activity and serum aldosterone were measured. Subsequently, urinary free cortisol (UFC) (normal range: <110[micro]g), urinary normetanephrine (normal range: 88-444 [micro]g/day) and urinary metanephrine (normal range: 52-341 [micro]g/day) were measured and the 1 mg overnight dexamethasone suppression test (DST) was performed. In subjects with non-suppressed cortisol levels, diurnal rhythm of cortisol was also evaluated (normal: midnight cortisol<7.5 [micro]g/dl).

The suppression in overnight DST was adequate when morning cortisol fell below 1.8 [micro]g/dl. When post DST cortisol was over 1.8 [micro]g/dl, 2-day 2 mg dexamethasone suppression test, involving the administration of 0.5 mg oral dexamethasone given every 6 hours for 48 hours, was performed. The patients with suppressed post DST cortisol levels were considered to have non-functional adenoma, if they additionally had at least one of the following criteria: (i) morning dehydroepiandrosterone sulfate (DHEA-S) levels[greater than or equal to]40 [micro]g/dl, (ii) non-suppressed plasma corticotrophin (normal value: [greater than or equal to]5 pg/ml) or (iii) UFC<110 [micro]g/day. In control subjects, HPA axis tests were not routinely investigated, as none of them had an apparent adrenal lesion on ultrasonography or clinical findings of a hormone excess syndrome.

Cushing's syndrome was based on a non-suppressed post DST cortisol (>1.8 [micro]g/dl), elevated urinary free cortisol (>110 [micro]g/day) and/or disturbed diurnal rhythm of cortisol secretion (midnight cortisol level>7.5 [micro]g/dl). Patients who had ACTH-dependent Cushing' syndrome were evaluated with bilateral petrosal sinus sampling. Subjects with undetectable ACTH levels were referred for adrenal imaging with CT.

Metabolic syndrome was defined according to the criteria established by the National Cholesterol Education Program Adult Treatment Panel III [17].

Distribution of continuous variables was assessed by the Kolmogorov-Smirnov normality test. According to the variable distribution, Independent samples t-test was used. Dichotomous variables were assessed with chi-square test. Logistic regression analysis was employed to assess independent variables that could be associated with development of NAFLD and metabolic syndrome. Statistical analysis was performed using SPSS, version 11.0 for Windows. A p value less than 0.05 was accepted as statistically significant.


In adenoma group, the mean adenoma diameter was 22.8[+ or -]10.0 mm. There were 61 (47.0%) subjects with right, 61 (47.0%) with left and 8 (6.0%) with bilateral adrenal adenomas.

Hormonal evaluation of participants with adrenal adenomas and Cushing's syndrome were as follows: morning cortisol (14.0[+or-]5.9 [micro]g/dl vs. 24.6[+or-]7.7 [micro]g/dl, p<0.001), midnight cortisol (5.7[+or-]3.6 [micro]g/dl vs. 23.8[+or-]5.2 [micro]g/dl, p<0.001), urinary free cortisol (41.3[+or-]26.4 [micro]g/day vs. 149.8[+or-]87.1 [micro]g/day, p<0.001) and post DST cortisol (1.6[+or-]1.1 [micro]g/dl vs. 17.8[+or-]9.0 [micro]g/dl, p<0.001), respectively.

Participants with Cushing's syndrome were significantly younger than the remaining subjects. Gender and BMI were comparable due to the inclusion criteria. Prevalence of Type 2 DM, hypertension and hyperlipidemia were similar in adenoma and control groups, while Type 2 DM (55.0% vs. 23.8%, p=0.007) and hypertension (59.3% vs. 85.0%, p=0.044) were more common in Cushing's syndrome group when compared to adenoma group (Table 1).
Table 1. Anthropometric and metabolic characteristics and
non-alcoholic fatty liver disease data of subjects with
non-functioning adrenal adenomas, Cushing Syndrome and control subjects

 Adrenal Cushing Control P * p
 adenoma Syndrome Subjects dagger double
 ( n = ( n = 20 ( n = dagger
 130 ) ) 170 )

Age 56.4[+ 45.1[+ or 57.2[+ or <0.001 0.517
 or -]11.3 -]9.8

Gender (F / M) 105 / 16 / 4 141 / 34 0.965 0.965

BMI (kg / 30.2[+ 32.5[+ or 31.0[+ or 0.152 0.163
m(2)) or -]6.5 -]4.4

Type 2 DM (%) 23.8 55.0 23.5 0.007 0.989

Hypertension 59.3 85.0 55.4 0.044 0.553

Hyperlipidemia 57.2 75.0 66.4 0.149 0.152

NAFLD n, (%) 40, 13, 67, 0.005 0.145
 (30.7) (65.0) (39.4)

AST 19.4[+ 27.7[+ or 21.4[+ or 0.002 0.042
 or -]15.9 -]7.2

ALT 22.9[+ 33.0[+ or 22.1[+ or <0.001 0.691
 or -]15.6 -]12.7

GGT 27.0[+ 76.4[+ or 27.8[+ or <0.001 0.795
 or -]60.3 -]23.7

Note that p [dagger] refers to comparisons between subject with adrenal
adenoma and Cushing Syndrome and p[double dagger] refers to comparisons
between subjects with adrenal adenoma and control subjects. Chi-square
or Independent samples T Test was used for comparisons BMI, body mass
index; DM, diabetes mellitus; NAFLD, non-alcoholic fatty liver disease

Non-alcoholic fatty liver prevalence was 30.7%, 65.0%, 39.4% in adenoma group, Cushing's syndrome group and control group, respectively. Aminotransferase levels and GGT were significantly elevated in Cushing's syndrome group when compared to adrenal adenoma group. Gamma-glutamyl transpeptidase and ALT levels were comparable between adrenal adenoma group and control group while AST level was slightly elevated in control group (Table 1). Severity of hepatosteatosis and its distribution among study groups are demonstrated in Figure 1. Severe hepatosteatosis was not detected in adenoma group or control group while did in 3 subjects (15%) with Cushing's syndrome. Similarly, prevalence of moderate hepatosteatosis (25%) was significantly elevated in Cushing's syndrome group compared to other groups. There was no significant difference regarding severity of hepatosteatosis between adenoma group and healthy controls.


In order to assess the effect of cortisol excess on the development of NAFLD, logistic regression analysis was performed in adenoma and Cushing's syndrome groups (n=150) (Table 2). In the first model using age, gender and hypercortisolism as independent variables, hypercortisolism was found to be the independent predictor of NAFLD development (beta=1.246, p=0.021, OR: 3.476). In model 2, age, gender, hypercortisolism, and metabolic syndrome were assessed. Metabolic syndrome remained as the independent factor associated with the development of NAFLD (beta=2.215, p<0.001, OR: 9.162). Lastly, third model investigating the effects of age, gender and hypercortisolism on the development of metabolic syndrome, hypercortisolism was the independent variable that predicted the development of metabolic syndrome (beta=2.358, p<0.004, OR: 10.571).
Table 2 Predictors of non-alcoholic fatty liver disease and metabolic
syndrome in non-functioning adrenal adenoma and Cushing Syndrome groups

 Beta OR P 95%CI

 Age -0.16 0.984 0.352 0.951-1.018
Model 1 Gender 0.307 1.359 0.519 0.535-3.541
NAFLD Hypercortisolism 1.246 3.476 0.021 1.204-10.036
 Age 0.522 1.686 0.069 0.926-1.003

Model 2 Gender 0.269 1.309 0.604 0.473-3.621
NAFLD Hypercortisolism 0.522 1.686 0.373 0.535-5.319
 Metabolic 2.215 9.162 <0.001 3.338-25.149
 Age 0.031 1.032 0.071 0.997-1.068

Model 3 Gender 0.255 1.290 0.603 0.494-3.370
Metabolic Hypercortisolism 2.358 10.571 0.004 2.162-51.688

NAFLD, non-alcoholic hepatosteatosis, OR, odds ratio


In this study, we hypothesized that subjects with non-functioning adrenal adenomas may feature increased prevalence of NAFLD. This based on two previous findings: the first one was the demonstration of subtle cortisol autonomy in even clinically silent adenomas (1,3,5,6); and the second was the findings attributable to the hypothalamic-pituitary-adrenal (HPA) axis alterations in subjects with NAFLD (8-11). Elevated levels of free fatty acids, insulin and several adipokines, as observed in metabolic syndrome, induce hydroxysteroid dehydrogenase type 1 (11[beta]-HSD1) gene expression in the liver. This stimulates the conversion of inactive cortisone to cortisol and facilities the action of glucocorticoids in liver resulting in increased glucose output, lipid synthesis and, finally, steatosis (18). In our study, we showed comparable NAFLD prevalence between non-functioning adenoma group and control subjects. We suggest that, this result was likely to be associated with similar rates of metabolic derangements and similar BMI between the groups as NAFLD is a consequence of insulin resistant state. This finding demonstrated that, the presence of a silent adrenal adenoma was not associated with additional risk of developing fatty liver beyond the consequences of metabolic syndrome and insulin resistant state.

Despite the clinical awareness of the close interrelation between Cushing's syndrome and fatty liver, true incidence remains unknown. In a previous report, Rockall et al. [19] demonstrated that 20% of patients had hepatic steatosis. However, this rate was not significantly different when compared to prevalence estimates reported to be 17%-33% in epidemiological studies [20]. In our study, we showed that individuals with Cushing's syndrome had nearly a 2-fold increase in NAFLD prevalence when compared to the remaining participants. Additionally, steatosis observed in hypercortisolemic subjects was more severe. Logistic regression analysis revealed that, hypercortisolemia strongly predicted the development of metabolic syndrome (OR: 10.571, p=0.004). However, when age, gender, hypercortisolemia and metabolic syndrome were assessed in a regression model for their possible effects on NAFLD development, metabolic syndrome remained as the sole independent predictor for the development of fatty liver (OR: 9.162, p<0.001). These results suggest that cortisol excess is related with the development of fatty liver, mainly through its unfavorable metabolic effects. These include their contrary effects on insulin action in several tissues. They increase the turnover between stored energy (glycogen, triglyceride) and freely available fuel (glucose, free fatty acids) for mitochondrial oxidation. Glucocorticoids also raise blood pressure and glucose and increase visceral adipose tissue that is strongly associated with insulin resistant state (21,22).

Two issues in our study may cause concern. The first one is the detection of steatosis by ultrasonography instead of CT or magnetic resonance imaging. Despite its limitations such as being operator dependent and the lack of providing quantitative information, it was demonstrated that sensitivity, specificity and positive predictive value of ultrasonography to detect steatosis was as high as 80 to 100% (23). Second issue was the lack of HPA axis parameters in control group. We did not perform any hormone measurements in control group because they did not have adrenal gland tumors or clinical findings related to any hormone excess syndromes.

In conclusion, we did not demonstrate an increased NAFLD prevalence in subjects with non functioning adrenal adenomas while apparent hypercortisolemia was associated with both increased prevalence and increased severity of NAFLD via its unfavorable metabolic effects. The causative relation between clinically non functioning adrenal adenomas and unfavorable metabolic status has been a debate so far. Despite several data regarding this condition, there are still unequivocal issues that need to be elucidated with further studies.


(1.) Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 2005;34:423-39.

(2.) Terzolo M, Osella G, Ali A, et al. Subclinical Cushing's syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) 1998;48:89-97.

(3.) Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002;87:998-1003.

(4.) Terzolo M, Reimondo G, Bovio S, and Angeli A. Subclinical Cushing's syndrome. Pituitary 2004;7:217-23.

(5.) Yener S, Comlekci A, Akinci B, et al. Non-functioning adrenal incidentalomas are associated with elevated D-dimer levels. J Endocrinol Invest 2009;32:338-43.

(6.) Yener S, Genc S, Akinci B, et al. Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine 2009;35:365-70.

(7.) Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-61.

(8.) Holt HB, Wild SH, Postle AD, et al. Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. Diabetologia 2007;50:1024-32.

(9.) Targher G, Bertolini L, Rodella S, et al. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006;64: 337-41.

(10.) Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. Diabet Med 2005;22:1146-50.

(11.) Zoppini G, Targher G, Venturi C, Zamboni C, Muggeo M. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol (Oxf) 2004;61:711-5.

(12.) Midorikawa S, Sanada H, Hashimoto S, et al. Analysis of cortisol secretion in hormonally inactive adrenocortical incidentalomas: study of in vitro steroid secretion and immunohistochemical localization of steroidogenic enzymes. Endocr J 2001;48:167-74.

(13.) Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996;24:25-9.

(14.) Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997;27:108-13.

(15.) SSaverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.

(16.) Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008;28:386-95.

(17.) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.

(18.) Iwasaki Y, Takayasu S, Nishiyama M, et al. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11betahydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008;285:10-8.

(19.) Rockall AG, Sohaib SA, Evans D, et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003;149:543-8.

(20.) Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.

(21.) Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007;157:545-59.

(22.) Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension 2000;36:912-6.

(23.) Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007;102:2716-7.

Serkan Yener, Abdurrahman Comlekci, Senem Ertilav, Mustafa Secil *, Mesut Akarsu **, Sena Yesil

Dokuz Eylul University, Faculty of Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir, Turkey * Dokuz Eylul University Faculty of Medicine, Department of Radiology, Izmir, Turkey ** Dokuz Eylul University Faculty of Medicine, Division of Gastroenterology, Department of Internal Medicine, Izmir, Turkey

Address for Correspondence: Serkan Yener MD, Dokuz Eylul University, School of Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir, Turkey Phone: +90 232 412 37 01 E-mail: Recevied: 12.08.2011 Accepted: 14.09.2011 Turkish Journal of Endocrinology and Metabolism, published by Galenos Publishing.
COPYRIGHT 2011 Galenos Yayinevi Tic. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Orginal Article/Ozgun Arastirma
Author:Yener, Serkan; Comlekci, Abdurrahman; Ertilav, Senem; Secil, Mustafa; Akarsu, Mesut; Yesil, Sena
Publication:Turkish Journal of Endocrinology and Metabolism
Date:Dec 1, 2011
Previous Article:Lack of association of vitamin d binding protein polymorphisms in egyptian children with type 1 diabetes/Misirli cocuklarda tip 1 diyabet ile D...
Next Article:Depression and anxiety in obese patients/Obezite hastalarinda anksiyete ve depresyon duzeyleri.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |